Skip to main content
Grant Details

Grant Number: 5P01CA206980-02 Interpret this number
Primary Investigator: Berwick, Marianne
Organization: University Of New Mexico Health Scis Ctr
Project Title: Integration of Clinical and Molecular Biomarkers for Melanoma Survival
Fiscal Year: 2018
Back to top


Abstract

Program Project Abstract/Summary We have brought together 12 institutions in order to promote a better understanding of the biology of melanoma and how that affects an individual?s survival. Our hypothesis is that primary melanomas will have molecular and clinical features that will allow the stratification of melanoma tumors at AJCC TNM Stages IIA/IIB/IIC/IIIA/IIIB, where there is little effective adjuvant therapy, into those with a good prognosis and those with poor prognosis. The current mortality rate for individuals diagnosed at these stages ranges between 18- 47% for Stages IIA/IIB/IIC and 32-78% for Stage IIIA/IIIB patients. The ability to improve clinical care and patient outcomes for these patients might be achieved by focusing on the identification and prioritization of biomarkers ? both molecular and clinical ? that might triage high risk patients for new adjuvant therapies. In this study, we will identify somatic tumor mutations, CNVs, an immune profile, methylation profiles, and microRNA/mRNA signatures in primary melanoma that are associated with prognosis, with the ultimate intent of translating this information into the clinic to personalize care. Currently, there is a dearth of studies in the melanoma field looking at epidemiologic/genomic factors and melanoma survival. In order to identify, confirm and develop such biomarkers, we have brought together 9 cohorts of melanoma patients at AJCC TNM stages IIA/IIB/IIC/IIIA/IIIB, comprising 1000 individuals, 500 of whom have died from their disease as of 2012 and 500 whom have lived at least 5 years. Patients will be frequency matched for stage. As we integrate data from multiple platforms, we will randomly divide the dataset into a training set (660 tumors, half aggressive and half non-aggressive) and a validation set (340 tumors, half aggressive and half non-aggressive). Significant findings in the training set will be replicated in the validation set. These patients have all been treated using standard-of-care surgery. All patients in this study will have adequate tumor tissue, germline DNA and clinical, pathologic and demographic information recorded. Our objective is to identify prognostic biomarkers associated with survival. The goal is to identify patients for whom more aggressive therapy prior to developing metastases would be relevant, that is would make a difference to their survival. Our central hypothesis is that melanoma prognosis is largely determined early in tumor development and that DNA and RNA markers, combined with clinicopathologic and protein characteristics in primary melanoma will add information to outcome prediction beyond the pathologic features used in AJCC tumor staging. We are taking an integrative approach to take advantage of and organize the large amount of information generated from each project. Such information will be available to clinicians and other investigators as soon as possible.

Back to top


Publications

Gene characteristics predicting missense, nonsense and frameshift mutations in tumor samples.
Authors: Gorlov I.P. , Pikielny C.W. , Frost H.R. , Her S.C. , Cole M.D. , Strohbehn S.D. , Wallace-Bradley D. , Kimmel M. , Gorlova O.Y. , Amos C.I. .
Source: Bmc Bioinformatics, 2018-11-19 00:00:00.0; 19(1), p. 430.
EPub date: 2018-11-19 00:00:00.0.
PMID: 30453881
Related Citations

Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Authors: Thomas N.E. , Edmiston S.N. , Tsai Y.S. , Parker J.S. , Googe P.B. , Busam K.J. , Scott G.A. , Zedek D.C. , Parrish E.A. , Hao H. , et al. .
Source: The American Journal Of Dermatopathology, 2018-09-11 00:00:00.0; , .
EPub date: 2018-09-11 00:00:00.0.
PMID: 30211730
Related Citations

A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis.
Authors: Zhao Y. , Schaafsma E. , Gorlov I.P. , Hernando E. , Thomas N.E. , Shen R. , Turk M.J. , Berwick M. , Amos C.I. , Cheng C. .
Source: Molecular Cancer Research : Mcr, 2018-08-31 00:00:00.0; , .
EPub date: 2018-08-31 00:00:00.0.
PMID: 30171176
Related Citations

Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
Authors: Gorlov I. , Orlow I. , Ringelberg C. , Hernando E. , Ernstoff M.S. , Cheng C. , Her S. , Parker J.S. , Thompson C.L. , Gerstenblith M.R. , et al. .
Source: Melanoma Research, 2018-07-02 00:00:00.0; , .
EPub date: 2018-07-02 00:00:00.0.
PMID: 29975213
Related Citations

Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
Authors: Thomas N.E. , Edmiston S.N. , Orlow I. , Kanetsky P.A. , Luo L. , Gibbs D.C. , Parrish E.A. , Hao H. , Busam K.J. , Armstrong B.K. , et al. .
Source: The Journal Of Investigative Dermatology, 2018-05-09 00:00:00.0; , .
EPub date: 2018-05-09 00:00:00.0.
PMID: 29753029
Related Citations




Back to Top